Selected article for: "antibody describe and immune response"
Author: Dang, Ha V.; Chan, Yee-Peng; Park, Young-Jun; Snijder, Joost; Da Silva, Sofia Cheliout; Vu, Bang; Yan, Lianying; Feng, Yan-Ru; Rockx, Barry; Geisbert, Thomas W.; Mire, Chad E.; Broder, Christopher C.; Veesler, David
Title: An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections
  • Cord-id: akzydy7l
  • Document date: 2019_9_30
    • ID: akzydy7l
    Snippet: Nipah virus (NiV) and Hendra virus (HeV) are zoonotic henipaviruses (HNVs) responsible for outbreaks of encephalitis and respiratory illness with fatality rates of 50–100%. No vaccines or licensed therapeutics currently exist to protect humans against NiV or HeV. HNVs enter host cells by fusing the viral and cellular membranes via the concerted action of the attachment (G) and fusion (F) glycoproteins, the main targets of the humoral immune response. Here, we describe the isolation and humaniz
    Document: Nipah virus (NiV) and Hendra virus (HeV) are zoonotic henipaviruses (HNVs) responsible for outbreaks of encephalitis and respiratory illness with fatality rates of 50–100%. No vaccines or licensed therapeutics currently exist to protect humans against NiV or HeV. HNVs enter host cells by fusing the viral and cellular membranes via the concerted action of the attachment (G) and fusion (F) glycoproteins, the main targets of the humoral immune response. Here, we describe the isolation and humanization of a potent monoclonal antibody cross-neutralizing NiV and HeV. Cryo-electron microscopy, triggering and fusion studies show the antibody binds to a prefusion-specific quaternary epitope, conserved in NiV F and HeV F glycoproteins, and prevents membrane fusion and viral entry. This work supports the importance of the HNV prefusion F conformation for eliciting a robust immune response and paves the way for using this antibody for prophylaxis and post-exposure therapy with NiV- and HeV-infected individuals.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and additional time: 1
    • absence presence and live virus: 1, 2
    • acid aspartic glutamic acid serine and acute sars cov respiratory syndrome coronavirus: 1
    • action mechanism and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mechanism and additional reference: 1
    • action mechanism and additional time: 1
    • action mechanism and live virus: 1, 2
    • acute sars cov respiratory syndrome coronavirus and additional reference: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and additional time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute sars cov respiratory syndrome coronavirus and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and live virus infection: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and local resolution: 1, 2, 3